Streamlined in vivo selection and screening of human prostate carcinoma avid phage particles for development of peptide based in vivo tumor imaging agents

Combinatorial Chemistry and High Throughput Screening

Volumn 14, Issue 1, 2011, Pages 9-21

  Newton Northup, Jessica R ^a   Figueroa, Said D ^a   Deutscher, Susan L ^b  

^a University of Missouri   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Fluorescent optical imaging; In vivo screening; PC 3 prostate carcinoma; Phage display; Peptides; SPECT; Tumor targeting

Indexed keywords

ALANYLASPARAGINYLGLYCYLVALYLPROLYLISOLEUCYLPROLYLPROLYLHISTIDYLPROLYLALANYLARGINYLALANYLALANYLARGININE IN 111; ALANYLLYSYLPROLYLLEUCYLALANYLSERYLPROLYLARGINYLGLUTAMYLTHREONYLGLYCYLALANYLSERYLGLUTAMINYLARGININE IN 111; ARGINYLALANYLLYSYLALANYLSERYLALANYLTHREONYLVALYLCYSTEINYLHISTIDYLLEUCYLSERYLASPARAGINYLPROLYLTYROSINE IN 111; ARGINYLLYSYLARGINYLALANYLPROLYLPROLYLPROLYLALANYLLEUCYLARGINYLTHREONYLALANYLPROLYLARGINYLSERINE IN 111; ARGINYLLYSYLSERYLLEUCYLPROLYLISOLEUCYLALANYLLEUCYLGLUTAMINYLLEUCYLHISTIDYLHISTIDYLSERYLTYROSYLASPARAGININE IN 111; ARGINYLPROLYLLYSYLLEUCYLLEUCYLHISTIDYLCYSTEINYLGLUTAMYLPROLYLSERYLPROLYLALANYLVALYLVALYLGLUTAMINE IN 111; ARGINYLVALYLMETHIONYLLYSYLHISTIDYLARGINYLTHREONYLPROLYLSERYLSERYLARGINYLTYROSYLGLUTAMINYLLYSYLPROLINE IN 111; DIAGNOSTIC AGENT; GLUTAMINYLHISTIDYLTHREONYLLEUCYLISOLEUCYLISOLEUCYLASPARTYLALANYLTHREONYLMETHIONYLPROLYLSERYLALANYLSERYLPROLINE IN 111; GLUTAMINYLSERYLGLYCYLMETHIONYLPROLYLGLUTAMINYLCYSTEINYLTYROSYLTHREONYLALANYLLEUCYLARGINYLPROLYLARGINYLVALINE IN 111; GLUTAMINYLSERYLPROLYLSERYLCYSTEINYLHISTIDYLMETHIONYLSERYLSERYLLEUCYLGLUTAMINYLCYSTEINYLTHREONYLGLUTAMINYLLEUCINE IN 111; GLUTAMINYLTHREONYLTYROSYLTHREONYLPROLYLTHREONYLLYSYLGLUTAMINYLSERYLPROLYLPROLYLMETHIONYLPROLYLARGINYLPROLINE IN 111; HISTIDYLVALYLTHREONYLSERYLTHREONYLLYSYLALANYLTRYPTOPHYLTYROSYLASPARTYLPROLYLSERYLGLUTAMINYLPROLYLLEUCINE IN 111; ISOLEUCYLLYSYLALANYLPROLYLASPARAGINYLPROLYLPROLYLSERYLVALYLSERYLTHREONYLLEUCYLPROLYLPROLYLARGININE IN 111; LEUCYLVALYLISOLEUCYLALANYLPROLYLMETHIONYLCYSTEINYLLYSYLPROLYLPROLYLPROLYLTYROSYLTHREONYLPROLYLGLUTAMINE IN 111; LYSYLASPARTYLPROLYLALANYLLEUCYLLEUCYLTHREONYLARGINYLSERYLPROLYLPROLYLSERYLALANYLARGINYLMETHIONINE IN 111; LYSYLGLUTAMYLMETHIONYLVALYLVALYLSERYLCYSTEINYLPROLYLPROLYLGLYCYLALANYLLEUCYLALANYLTYROSYLSERINE IN 111; LYSYLGLYCYLMETHIONYLARGINYLMETHIONYLARGINYLLEUCYLALANYLISOLEUCYLGLYCYLPROLYLASPARTYLSERYLALANINE IN 111; LYSYLLEUCYLVALYLCYSTEINYLVALYLSERYLALANYLASPARAGINYLPHENYLALANYLGLUTAMINYLSERYLGLYCYLVALYLPROLYLHISTIDINE IN 111; METHIONYLASPARAGINYLARGINYLLEUCYLPROLYLASPARTYLPHENYLALANYLTHREONYLARGINYLLEUCYLPROLYLPROLYLTYROSYLSERYLPROLINE IN 111; PROLYLARGINYLASPARTYLSERYLMETHIONYLLEUCYLPHENYLALANYLMETHIONYLPROLYLCYSTEINYLLYSYLPHENYLALANYLARGINYLPROLYLMETHIONINE IN 111; PROLYLMETHIONYLARGINYLPROLYLLYSYLGLYCYLPROLYLASPARTYLTHREONYLLEUCYLLEUCYLTYROSYLTHREONYLLEUCYLPROLINE IN 111; PROLYLVALYLLEUCYLISOLEUCYLPHENYLALANYLLYSYLLYSYLISOLEUCYLVALYLLEUCYLTHREONYLALANYLPROLYLVALYLALANINE IN 111; SERYLARGINYLLEUCYLTHREONYLARGINYLASPARAGINYLASPARTYLMETHIONYLVALYLTHREONYLGLYCYLCYSTEINYLMETHIONYLCYSTEINE IN 111; THREONYLASPARAGINYLSERYLSERYLARGINYLPROLYLLEUCYLSERYLLYSYLSERYLARGINYLGLUTAMINYLTYROSYLARGINYLCYSTEINE IN 111; THREONYLPROLYLGLYCYLLEUCYLASPARTYLALANYLALANYLVALYLPHENYLALANYLTRYPTOPHYLSERYLLEUCYLGLYCYLSERYLGLUTAMINE IN 111; THREONYLSERYLMETHIONYLISOLEUCYLTYROSYLARGINYLPROLYLHISTIDYLASPARAGINYLVALYLGLUTAMINYLTHREONYLLEUCYLLEUCYLHISTIDINE IN 111; TYROSYLLEUCYLARGINYLISOLEUCYLTHREONYLSERYLTHREONYLPROLYLHISTIDYLLYSYLTYROSYLLEUCYLTHREONYLGLUTAMINYLARGININE IN 111; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALYLISOLEUCYLLEUCYLASPARAGINYLTRYPTOPHYLARGINYLPROLYLSERYLCYSTEINYLLEUCYLVALYLTHREONYLCYSTEINYLHISTIDYLGLUTAMINE IN 111;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BINDING AFFINITY; CANCER DIAGNOSIS; CONTROLLED STUDY; CYTOTOXICITY; DRUG DISTRIBUTION; DRUG SCREENING; DRUG SYNTHESIS; FLUORESCENCE IMAGING; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOLECULAR CLONING; MOUSE; NONHUMAN; PHAGE DISPLAY; PREDICTION; PRIORITY JOURNAL; PROSTATE CARCINOMA; SCID MOUSE; SIGNAL NOISE RATIO; SINGLE PHOTON EMISSION COMPUTER TOMOGRAPHY;

MUS;

EID: 79751481946     PISSN: 13862073     EISSN: None     Source Type: Journal    
DOI: 10.2174/1386207311107010009     Document Type: Article

References (47)

1. Cepeda, V.; Fuertes, M.A.; Castilla, J.; Alonso, C.; Quevedo, C.; Perez, J.M. Biochemical mechanisms of cisplatin cytotoxicity. Anticancer Agents Med. Chem., 2007, 7(1), 3-18. (Pubitemid 46062402)
2. Hakomori, S. Tumor-associated carbohydrate antigens defining tumor malignancy: Basis for development of anti-cancer vaccines. Adv. Exp. Med. Biol., 2001, 491, 369-402.
3. Samoylova, T.I.; Morrison, N.E.; Cox, N.R. Molecular markers of glial tumors: Current targeting strategies. Curr. Med. Chem., 2003, 10(10), 831-843. (Pubitemid 36443238)
4. Besse, B.; Ropert, S.; Soria, J.C. Targeted therapies in lung cancer. Ann. Oncol., 2007, 18(Suppl. 9), ix135-142.
5. Bradford, T.J.; Tomlins, S.A.; Wang, X.; Chinnaiyan, A.M. Molecular markers of prostate cancer. Urol. Oncol., 2006, 24(6), 538-551. (Pubitemid 44810016)
6. Newton, J.R.; Deutscher, S.L. Molecular targets and biomarkers for imaging cancer: Phage peptide display. Springer-Verlag: Berlin, 2006; Vol. Molecular Imaging.
7. Stamey, T.A.; Caldwell, M.; McNeal, J.E.; Nolley, R.; Hemenez, M.; Downs, J. The prostate specific antigen era in the united states is over for prostate cancer: What happened in the last 20 years? J. Urol., 2004, 172(4 Pt 1), 1297-1301. (Pubitemid 39249701)
8. Slovin, S. F. Targeting novel antigens for prostate cancer treatment: Focus on prostate-specific membrane antigen. Expert Opin. Ther. Targets, 2005, 9(3), 561-570. (Pubitemid 40883153)
9. Wang, X.; Yin, L.; Rao, P.; Stein, R.; Harsch, K.M.; Lee, Z.; Heston, W.D. Targeted treatment of prostate cancer. J. Cell. Biochem., 2007, 102(3), 571-579. (Pubitemid 47557412)
10. Michener, C.M.; Ardekani, A.M.; Petricoin, E.F., 3rd; Liotta, L.A.; Kohn, E.C. Genomics and proteomics: Application of novel technology to early detection and prevention of cancer. Cancer Detect. Prev., 2002, 26, 249-255. (Pubitemid 36211103)
11. Kohn, E.C.; Azad, N.; Annunziata, C.; Dhamoon, A.S.; Whiteley, G. Proteomics as a tool for biomarker discovery. Dis. Markers, 2007, 23(5-6), 411-417. (Pubitemid 350171262)
12. Samoylova, T.I.; Morrison, N.E.; Globa, L.P.; Cox, N.R. Peptide phage display: Opportunities for development of personalized anticancer strategies. Anticancer Agents Med. Chem., 2006, 6(1), 9-17. (Pubitemid 43796653)
13. Landon, L.A.; Zou, J.; Deutscher, S.L. Is phage display technology on target for developing peptide-based cancer drugs? Curr. Drug Discov. Technol., 2004, 1(2), 113-132.
14. Messeguer, A.; Cortes, N. Combinatorial chemistry in cancer research. Clin. Transl. Oncol., 2007, 9(2), 83-92.
15. Yip, Y.L.; Ward, R.L. Application of phage display technology to cancer research. Curr. Pharm. Biotechnol., 2002, 3(1), 29-43. (Pubitemid 34234781)
16. Zaccaro, L.; Del Gatto, A.; Pedone, C.; Saviano, M. Peptides for tumour therapy and diagnosis: Current status and future directions. Curr. Med. Chem., 2009, 16(7), 780-795.
17. Liu, Z.; Wu, K. Peptides homing to tumor vasculature: Imaging and therapeutics for cancer. Rec. Pat. Anticancer Drug Discov., 2008, 3(3), 202-208.
18. Reubi, J.C.; Maecke, H.R. Peptide-based probes for cancer imaging. J. Nucl. Med., 2008, 49(11), 1735-1738.
19. Aina, O.H.; Liu, R.; Sutcliffe, J.L.; Marik, J.; Pan, C.X.; Lam, K.S. From combinatorial chemistry to cancer-targeting peptides. Mol. Pharm., 2007, 4(5), 631-651.
20. Smith, G.P. Lab homepage, http://www.Biosci.Missouri.Edu/smithgp/.
21. Landon, L.A.; Deutscher, S.L. Combinatorial discovery of tumor targeting peptides using phage display. J. Cell. Biochem., 2003, 90(3), 509-517. (Pubitemid 37243698)
22. Deutscher, S.L. Phage display in molecular imaging and diagnosis of cancer. Chem. Rev., 2010, 110(5), 3196-3211.
23. Newton, J.R.; Kelly, K.A.; Mahmood, U.; Weissleder, R.; Deutscher, S.L. In vivo selection of phage for the optical imaging pc-3 human prostate carcinoma in mice. Neoplasia, 2006, 8(9), 772-780. (Pubitemid 44465528)
24. Kelly, K.A.; Clemons, P.A.; Yu, A.M.; Weissleder, R. Highthroughput identification of phage-derived imaging agents. Mol. Imaging, 2006, 5(1), 24-30.
25. Landon, L.A.; Harden, W.; Illy, C.; Deutscher, S.L. Highthroughput fluorescence spectroscopic analysis of affinity of peptides displayed on bacteriophage. Anal. Biochem., 2004, 331 (1), 60-67. (Pubitemid 38881558)
26. Jaye, D.L.; Geigerman, C.M.; Fuller, R.E.; Akyildiz, A.; Parkos, C.A. Direct fluorochrome labeling of phage display library clones for studying binding specificities: Applications in flow cytometry and fluorescence microscopy. J. Immunol. Methods, 2004, 295(1- 2), 119-127. (Pubitemid 41057774)
27. Samoylov, A.M.; Samoylova, T.I.; Hartell, M.G.; Pathirana, S.T.; Smith, B.F.; Vodyanoy, V. Recognition of cell-specific binding of phage display derived peptides using an acoustic wave sensor. Biomol. Eng., 2002, 18(6), 269-272. (Pubitemid 34158561)
28. Newton, J.; Deutscher, S.L. Phage peptide display. Handb. Exp. Pharmacol., 2008, (185 Pt 2), 145-163.
29. Smith, G.P. Filamentous fusion phage: Novel expression vectors that display cloned antigens on the virion surface. Science, 1985, 228(4705), 1315-1317. (Pubitemid 15000355)
30. Landon, L.A.; Peletskaya, E.N.; Glinsky, V.V.; Karasseva, N.; Quinn, T.P.; Deutscher, S.L. Combinatorial evolution of high affinity peptides that bind to the thomsen-friedenreich carcinoma antigen. J. Protein Chem., 2003, 22, 193-204. (Pubitemid 38115216)
31. Zou, J.; Dickerson, M.T.; Owen, N.K.; Landon, L.A.; Deutscher, S.L. Biodistribution of filamentous phage peptide libraries in mice. Mol. Biol. Rep., 2004, 31(2), 121-129. (Pubitemid 38881802)
32. Christianson, D.R.; Ozawa, M. G.; Pasqualini, R.; Arap, W. Techniques to decipher molecular diversity by phage display. Methods Mol. Biol., 2007, 357, 385-406. (Pubitemid 350183263)
33. Zurita, A. J.; Arap, W.; Pasqualini, R. Mapping tumor vascular diversity by screening phage display libraries. J. Control Release, 2003, 91 (1-2), 183-186. (Pubitemid 37288889)
34. Karasseva, N.; Glinsky, V.V.; Chen, N.X.; Komatireddy, R.; Quinn, T.P. Identification and characterization of peptides that bind human erbb-2 selected from a bacteriophage display library. J. Protein Chem., 2002, 21, 287-296. (Pubitemid 34839925)
35. Kumar, S.R.; Quinn, T.P.; Deutscher, S.L. Evaluation of an 111inradiolabeled peptide as a targeting and imaging agent for erbb-2 receptor expressing breast carcinomas. Clin. Cancer Res., 2007, 13(20), 6070-6079. (Pubitemid 350075064)
36. Nasu, K.; Tanji, N.; Nishioka, R.; Wang, J.; Yanagihara, Y.; Ozawa, A.; Yokoyama, M.; Sakayama, K. Expression of erbb proteins in human prostate. Arch. Androl., 2006, 52(3), 185-190.
37. Hartmann, F.; Horak, E.M.; Cho, C.; Lupu, R.; Bolen, J.B.; Stetler- Stevenson, M.A.; Pfreundschuh, M.; Waldmann, T.A.; Horak, I.D. Effects of the tyrosine-kinase inhibitor geldanamycin on ligandinduced her-2/neu activation, receptor expression and proliferation of her-2-positive malignant cell lines. Int. J. Cancer, 1997, 70 (2), 221-229. (Pubitemid 27107421)
38. Beerli, R.R.; Graus-Porta, D.; Woods-Cook, K.; Chen, X.; Yarden, Y.; Hynes, N.E. Neu differentiation factor activation of erbb-3 and erbb-4 is cell specific and displays a differential requirement for erbb-2. Mol. Cell. Biol., 1995, 15(12), 6496-6505.
39. Tran, T.A.; Rosik, D.; Abrahmsen, L.; Sandstrom, M.; Sjoberg, A.; Wallberg, H.; Ahlgren, S.; Orlova, A.; Tolmachev, V. Design, synthesis and biological evaluation of a multifunctional her2- specific affibody molecule for molecular imaging. Eur. J. Nucl. Med. Mol. Imaging, 2009, 36(11), 1864-1873.
40. Rusnak, D.W.; Alligood, K.J.; Mullin, R.J.; Spehar, G.M.; Arenas- Elliott, C.; Martin, A.M.; Degenhardt, Y.; Rudolph, S.K.; Haws, T.F., Jr.; Hudson-Curtis, B.L.; Gilmer, T.M. Assessment of epidermal growth factor receptor (egfr, erbb1) and her2 (erbb2) protein expression levels and response to lapatinib (tykerb, gw572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif., 2007, 40(4), 580-594. (Pubitemid 47063294)
41. Danielsen, A.J.; Maihle, N.J. The egf/erbb receptor family and apoptosis. Growth Factors, 2002, 20(1), 1-15. (Pubitemid 34693055)
42. Chae, H.J.; Kang, J.S.; Byun, J.O.; Han, K.S.; Kim, D.U.; Oh, S.M.; Kim, H.M.; Chae, S.W.; Kim, H.R. Molecular mechanism of staurosporine-induced apoptosis in osteoblasts. Pharmacol. Res., 2000, 42(4), 373-381.
43. Smith, G.P.; Petrenko, V.A. Phage display. Chem. Rev., 1997, 97(2), 391-410. (Pubitemid 127659250)
44. Sobel, R.E.; Sadar, M.D. Cell lines used in prostate cancer research: A compendium of old and new lines - part 1. J. Urol., 2005, 173(2), 342-359.
45. Kim, I.Y.; Kim, B.C.; Seong, D.H.; Lee, D.K.; Seo, J.M.; Hong, Y.J.; Kim, H.T.; Morton, R.A.; Kim, S.J. Raloxifene, a mixed estrogen agonist/antagonist, induces apoptosis in androgenindependent human prostate cancer cell lines. Cancer Res., 2002, 62(18), 5365-5369. (Pubitemid 35024614)
46. Mao, C.; Flynn, C.E.; Hayhurst, A.; Sweeney, R.; Qi, J.; Georgiou, G.; Iverson, B.; Belcher, A.M. Viral assembly of oriented quantum dot nanowires. Proc. Natl. Acad. Sci. USA, 2003, 100(12), 6946-6951. (Pubitemid 36706373)
47. Langer, M.; Beck-Sickinger, A.G. Peptides as carrier for tumor diagnosis and treatment. Curr. Med. Chem. Anticancer Agents, 2001, 1, 71-93.